EP3790538A4 - Procédés de modulation des taux plasmatiques de métabolites de tétrabénazine au moyen de bupropion - Google Patents

Procédés de modulation des taux plasmatiques de métabolites de tétrabénazine au moyen de bupropion Download PDF

Info

Publication number
EP3790538A4
EP3790538A4 EP19819780.8A EP19819780A EP3790538A4 EP 3790538 A4 EP3790538 A4 EP 3790538A4 EP 19819780 A EP19819780 A EP 19819780A EP 3790538 A4 EP3790538 A4 EP 3790538A4
Authority
EP
European Patent Office
Prior art keywords
bupropion
modulating
methods
plasma levels
tetrabenazine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP19819780.8A
Other languages
German (de)
English (en)
Other versions
EP3790538A1 (fr
Inventor
Herriot TABUTEAU
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Axsome Therapeutics Inc
Original Assignee
Axsome Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Axsome Therapeutics Inc filed Critical Axsome Therapeutics Inc
Publication of EP3790538A1 publication Critical patent/EP3790538A1/fr
Publication of EP3790538A4 publication Critical patent/EP3790538A4/fr
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
EP19819780.8A 2018-06-10 2019-06-10 Procédés de modulation des taux plasmatiques de métabolites de tétrabénazine au moyen de bupropion Pending EP3790538A4 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862682998P 2018-06-10 2018-06-10
US201862683399P 2018-06-11 2018-06-11
PCT/US2019/036406 WO2019241162A1 (fr) 2018-06-10 2019-06-10 Procédés de modulation des taux plasmatiques de métabolites de tétrabénazine au moyen de bupropion

Publications (2)

Publication Number Publication Date
EP3790538A1 EP3790538A1 (fr) 2021-03-17
EP3790538A4 true EP3790538A4 (fr) 2021-06-30

Family

ID=68843534

Family Applications (1)

Application Number Title Priority Date Filing Date
EP19819780.8A Pending EP3790538A4 (fr) 2018-06-10 2019-06-10 Procédés de modulation des taux plasmatiques de métabolites de tétrabénazine au moyen de bupropion

Country Status (17)

Country Link
EP (1) EP3790538A4 (fr)
JP (2) JP2021529826A (fr)
KR (2) KR20240034871A (fr)
CN (1) CN112292121A (fr)
AU (2) AU2019284477B2 (fr)
BR (1) BR112020025064A2 (fr)
CA (1) CA3101375A1 (fr)
CL (1) CL2020003189A1 (fr)
CO (1) CO2021000037A2 (fr)
CR (1) CR20200616A (fr)
EC (1) ECSP20082568A (fr)
IL (1) IL279332A (fr)
MX (1) MX2020013385A (fr)
NI (1) NI202000095A (fr)
PE (1) PE20210370A1 (fr)
SG (1) SG11202011762VA (fr)
WO (1) WO2019241162A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20200345663A1 (en) * 2018-06-10 2020-11-05 Axsome Therapeutics, Inc. Methods of modulating tetrabenazine metabolites plasma levels using bupropion

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160287574A1 (en) * 2015-03-06 2016-10-06 Auspex Pharmaceuticals, Inc. Methods for the treatment of abnormal involuntary movement disorders

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2462611A (en) * 2008-08-12 2010-02-17 Cambridge Lab Pharmaceutical composition comprising tetrabenazine
JP2013501810A (ja) * 2009-08-12 2013-01-17 ヴァリーント インターナショナル（バルバドス）エスアールエル 医薬組成物
US9707191B2 (en) * 2013-11-05 2017-07-18 Antecip Bioventures Ii Llc Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
US10105327B2 (en) * 2013-11-05 2018-10-23 Antecip Bioventures Ii Llc Compositions and methods for increasing the metabolic lifetime of dextromethorphane and related pharmacodynamic effects
US9732031B2 (en) * 2013-12-20 2017-08-15 Deuterx, Llc Methods of treating neurological and other disorders using enantiopure deuterium-enriched bupropion
MY189806A (en) * 2015-06-23 2022-03-08 Neurocrine Biosciences Inc Vmat2 inhibitors for treating neurological diseases or disorders

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160287574A1 (en) * 2015-03-06 2016-10-06 Auspex Pharmaceuticals, Inc. Methods for the treatment of abnormal involuntary movement disorders

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
ANONYMOUS: "Austedo TM (Deutetrabenazine) tablets for oral use", INTERNET CITATION, 1 April 2017 (2017-04-01), XP002784607, Retrieved from the Internet <URL:https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208082s000lbl.pdf> [retrieved on 20180911] *
See also references of WO2019241162A1 *
VIVIENNE SHEN ET AL: "Articles Safety and Efficacy of Tetrabenazine and Use of Concomitant Medications During Long-Term, Open-Label Treatment of Chorea Associated with Huntington's and Other Diseases", 22 October 2013 (2013-10-22), XP055321497, Retrieved from the Internet <URL:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3822048/pdf/tre-03-191-4337-1.pdf> [retrieved on 20161122] *
WYANT KARA J ET AL: "Huntington's Disease-Update on Treatments", CURRENT NEUROLOGY AND NEUROSCIENCE REPORTS, PHILADELPHIA, PA. : CURRENT SCIENCE INC, US, vol. 17, no. 4, 21 March 2017 (2017-03-21), pages 1 - 11, XP036201912, ISSN: 1528-4042, [retrieved on 20170321], DOI: 10.1007/S11910-017-0739-9 *

Also Published As

Publication number Publication date
KR20240034871A (ko) 2024-03-14
JP2021529826A (ja) 2021-11-04
AU2019284477A1 (en) 2021-01-28
CL2020003189A1 (es) 2021-05-28
MX2020013385A (es) 2021-05-27
SG11202011762VA (en) 2020-12-30
NI202000095A (es) 2021-06-22
BR112020025064A2 (pt) 2021-03-23
CN112292121A (zh) 2021-01-29
CA3101375A1 (fr) 2019-12-19
AU2022268331A1 (en) 2022-12-15
CO2021000037A2 (es) 2021-01-18
AU2019284477B2 (en) 2022-08-11
IL279332A (en) 2021-01-31
JP2024059744A (ja) 2024-05-01
WO2019241162A1 (fr) 2019-12-19
KR20210018914A (ko) 2021-02-18
PE20210370A1 (es) 2021-02-26
CR20200616A (es) 2021-03-15
ECSP20082568A (es) 2021-02-26
EP3790538A1 (fr) 2021-03-17

Similar Documents

Publication Publication Date Title
EP3830728A4 (fr) Remédiation d&#39;attaques de recharge de vidage
EP3768854A4 (fr) Modulation de l&#39;expression de hsd17b13
EP3852689A4 (fr) Procédé de chirurgie
EP3853365A4 (fr) Modulateurs de l&#39;expression de pnpla3
EP3899024A4 (fr) Modulateurs de l&#39;expression de hsd17b13
EP3943015A4 (fr) Instrument d&#39;ancrage
EP3876747A4 (fr) Procédés de modulation de métabolites gastro-intestinaux
EP3893883A4 (fr) Méthodes pour le traitement de la dépression
EP3619883A4 (fr) Sélection de forme d&#39;onde pour communications de liaison montante
EP3799570A4 (fr) Modulateurs de l&#39;expression d&#39;apol1
EP3781566A4 (fr) Composés modulateurs allostériques positifs à gabaa, procédés de production et d&#39;utilisations associés
EP3601569A4 (fr) Modulateurs de l&#39;expression de pcsk9
EP4017301A4 (fr) Appareil vaporisateur
EP3758704A4 (fr) Modulateurs de l&#39;expression d&#39;irf4
EP3934632A4 (fr) Eskétamine pour le traitement de la dépression
EP4082457A4 (fr) Instrument de néostomie
EP3979998A4 (fr) Modulateurs du complexe swell1-lrrc8
EP3880821A4 (fr) Modulateurs de l&#39;expression d&#39;irf5
EP3947684A4 (fr) Composés et méthodes de modulation de ube3a-ats
EP3911360A4 (fr) Procédés de modulation de la réponse aux corticostéroïdes
EP3790538A4 (fr) Procédés de modulation des taux plasmatiques de métabolites de tétrabénazine au moyen de bupropion
EP3775204A4 (fr) Modulateurs de l&#39;expression de l&#39;ezh2
EP3880211A4 (fr) Modulateurs de l&#39;expression de foxp3
EP3894418A4 (fr) Préparation de triiodosilanes
EP3863043A4 (fr) Suscepteur

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20201209

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

A4 Supplementary search report drawn up and despatched

Effective date: 20210528

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/137 20060101AFI20210521BHEP

Ipc: A61K 31/4375 20060101ALI20210521BHEP

Ipc: A61P 25/14 20060101ALI20210521BHEP

Ipc: A61P 25/24 20060101ALI20210521BHEP

Ipc: A61P 25/28 20060101ALI20210521BHEP

Ipc: A61K 31/4745 20060101ALI20210521BHEP

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40042810

Country of ref document: HK

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230515

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20231201